期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 30, 期 10, 页码 1467-1472出版社
WILEY
DOI: 10.1111/jgh.13008
关键词
IL-6; IL-8; infliximab; MIP-1; ulcerative colitis
资金
- Ministry of Education, Culture, Sports, Sciences, and Technology of Japan [25460418]
- Grants-in-Aid for Scientific Research [25460418] Funding Source: KAKEN
Background and AimInfliximab is an established therapy for ulcerative colitis (UC). The aim of this study was to examine various serum cytokine levels and to identify possible markers predictive of therapeutic efficacy of infliximab for UC patients. MethodsTwenty-one patients with moderately active UC were given intravenous infliximab (5mg/kg) at 0, 2, and 6 weeks as induction therapy. The serum levels of 17 cytokines were determined using a Bio-Plex suspension array system before and 8 weeks after induction therapy. Partial Mayo score (PMS) and serum C-reactive protein levels were used for the determination of clinical activities at 0 and 8 weeks after the treatment. The overall therapeutic effect was determined at 26 weeks according to the PMS. ResultsThe median value of the PMS decreased significantly 8 weeks after the treatment (from 6 to 1.5, P<0.05). However, C-reactive protein levels did not change significantly. Levels of serum interleukin (IL)-8 (P<0.05) and macrophage inflammatory protein-1 (P<0.005) significantly decreased 8 weeks after the induction. Serum levels of the other 15 cytokines did not change significantly. At 26 weeks, 13 of 20 patients (65%) were responders while 7 patients were non-responders. Levels of serum IL-6 at 8 weeks were significantly lower in responders than in non-responders (P<0.05). ConclusionsSerum IL-8 and macrophage inflammatory protein-1 seem to be sensitive markers for UC patients treated with infliximab, while IL-6 at 8 weeks after induction therapy may be predictive of subsequent response to infliximab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据